Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

By Dr. Matthew Watson

Follow this link:
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 - January 14th, 2025
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - January 14th, 2025
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - January 14th, 2025
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - January 14th, 2025
ProMIS Neurosciences Issues Letter to Shareholders - January 14th, 2025
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - January 14th, 2025
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer - January 14th, 2025
Correction: GUERBET : Financial agenda for 2025 - January 14th, 2025
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without... - January 14th, 2025
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - January 14th, 2025
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - January 14th, 2025
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s... - January 14th, 2025
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - January 14th, 2025
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - January 14th, 2025
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
Idorsia publishes an invitation to a bondholder meeting - January 14th, 2025
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy... - January 14th, 2025
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 5th, 2025
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 5th, 2025
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® - January 5th, 2025
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - January 5th, 2025
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - January 5th, 2025
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - January 5th, 2025
Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc. - January 5th, 2025
VALNEVA Declaration of shares and voting rights: December 31, 2024 - January 5th, 2025
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Procaps Group Receives Additional Delinquency Letter - January 5th, 2025
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 5th, 2025
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - January 5th, 2025
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week - January 5th, 2025
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 5th, 2025
BriaCell Announces Proposed Effective Date of Share Consolidation - January 5th, 2025
PharmaTher Announces Grant of Stock Options - January 5th, 2025
Oculis Publishes Notification of Major Changes in Voting Rights - January 5th, 2025
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 27th, 2024
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - December 27th, 2024
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - December 27th, 2024
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis - December 27th, 2024
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million - December 27th, 2024
Abivax Announces a Change to the Composition of its Board of Directors - December 27th, 2024
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial - December 27th, 2024
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - December 27th, 2024
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - December 27th, 2024
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. - December 27th, 2024
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation - December 27th, 2024
Optinose Announces 1-for-15 Reverse Stock Split - December 27th, 2024
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - December 27th, 2024
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing... - December 27th, 2024
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in... - December 27th, 2024
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - December 27th, 2024
Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering - December 27th, 2024
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating... - December 27th, 2024
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally - December 18th, 2024
Vaccinex Announces Receipt of Delisting Notification from Nasdaq - December 18th, 2024
Adia Nutrition Unveils Exclusive Artwork by Renowned Performance Artist Rock Demarco at First Clinic - December 18th, 2024
NYMOX Announces Trading Resumed and New Listing on OTCQB Market - December 18th, 2024
Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy - December 18th, 2024
AB Science provides a summary of the webcast held on December 16, 2024 - December 18th, 2024
Ultimovacs ASA – Mandatory notification of trade - December 18th, 2024
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare... - December 18th, 2024
Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA - December 18th, 2024
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18,... - December 18th, 2024
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - December 18th, 2024
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - December 18th, 2024
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic... - December 18th, 2024
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - December 18th, 2024
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - December 18th, 2024
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - December 18th, 2024
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology - December 18th, 2024
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution - December 18th, 2024
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP - December 9th, 2024

Global News Feed commento

Comments Off | data

January 14th, 2025

About... Dr. Matthew Watson

This author published 5972 posts in this site.

Comments are closed.

Previous post - Next post

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites